Insuficiența cardiacă și axa inimă-creier

Interactiunile bidirectionale inima-creier in IC

Relatia inima-creier nu este unidirectionala — IC produce leziuni cerebrale, dar si disfunctia cerebrala agraveza IC printr-un cerc vicios complex:

IC → afectare cerebrala:

• Debit cardiac redus → hipoperfuzie cerebrala cronica → declin cognitiv, dementa vasculara
• Embolism cardiogen din FA asociata IC sau din tromboza VS → AVC ischemic
• Activarea neuroumorala (RAAS, sistem nervos simpatic) → hipertensiune, ateroscleroza cerebrovasculara
• Inflamatie sistemica din IC → neuroinflammation, disfunctie colinergica corticala

Afectare cerebrala → agravare IC:

• Disfunctia frontala si executiva → scadere aderenta la tratament, incapacitatea de a urmari protocolul de auto-monitoring (greutate zilnica, restrictie lichide)
• Depresia si anxietatea (frecvente in IC) → activare neuroumorala crescuta, inflamatie, reducerea activitatii fizice
• Disfunctia autonoma cerebrala → tahicardie, aritmii ventriculare, cresterea activarii simpatice cardiace

Declinul cognitiv si dementa in IC

Incidenta declinului cognitiv la pacientii cu IC: 50–75% prezinta dovezi de disfunctie cognitiva la testari neuropsihologice formale, dar numai 20–40% sunt diagnosticati clinic. Domeniile cognitive cele mai afectate: memoria episodica, atentia si viteza de procesare, functiile executive (planificare, atentie divisa), fluenta verbala.

Mecanismele specifice IC care contribuie la dementa:

• Hipoperfuzie cerebrala cronica → pierdere de materie alba (white matter hyperintensities la RMN), infarct silentios, atrofie cortexului prefrontal
• Embolismul microembolic repetat din trombi VS sau FA asociata IC → microinfarctizare cerebrala silentioasa
• Biomarkeri de lezare neuronala (S-100B, NSE) crescuti in IC severa — semn de lezare hematoencefalica cronica prin hipoperfuzie

Depresia si anxietatea in IC — bidirectionalmente

Depresia majora afecteaza 20–35% din pacientii cu IC (fata de 5–8% in populatia generala). Anxietatea: 30–40%. Impactul depresiei in IC:

• Risc de mortalitate de 2–3 ori mai mare la IC cu depresie vs. IC fara depresie, independent de severitatea IC
• Spitalizari mai frecvente, calitate a vietii mai scazuta
• Activarea neuroumorala amplificata (cortizol crescut, aldosteron) → remodelare VS accelerata

Managementul depresiei in IC: ISRS (escitalopram, sertraline) sunt siguri si pot ameliora simptomele depresive; venlafaxina si mirtazapina cu precautie; TCA contraindicate (efecte antiaritmice proaritmice). Exercitiul fizic supervizat (cardiorecuperare) amelioreaza depresia si anxietatea concomitent cu beneficiile fizice cardiovasculare.

Implicatii pentru managementul IC

• Evaluarea cognitiva de rutina cu teste scurte (MMSE, MoCA) la pacientii cu IC — identificarea disfunctiei cognitive ghideaza simplificarea schemei terapeutice si implicarea familiei
• Screeningul depresiei (PHQ-9, BDI) la pacientii cu IC — tratamentul depresiei imbunatateste aderenta, calitatea vietii si potentila mortalitatea
• Cardiorecuperarea fizica abordeaza concomitent IC si complicatiile cerebrale (imbunatatire cognitie, reducere depresie)
• Anticoagularea pentru FA si FEVS redusa (DOAC, warfarina) previne embolismul cerebral si AVC

Concluzii

Revizuirea din QJM (2023) subliniaza caracterul bidirectional al axei inima-creier in IC: IC produce afectare cognitiva, AVC si depresie prin hipoperfuzie, embolism si activare neuroumorala, iar disfunctia cerebrala agraveza IC prin aderenta scazuta si activare autonoma. Managementul comprehensiv al IC trebuie sa incluoa evaluarea cognitiva regulata, screeningul pentru depresie si anxietate, si interventii terapeutice adresand simultan componenta cardiaca si cerebrala a axei inima-creier.

Heart failure and the heart-brain axis (QJM, November 2023, PMID 37481714) provides cardiologists with a structured framework for understanding and managing the cognitive, psychiatric, and neurological complications that frequently accompany advanced heart failure — complications that bidirectionally worsen cardiac outcomes through impaired treatment adherence, neurohormonal amplification, and autonomic dysfunction. Integrating cognitive assessment (MoCA, MMSE) and depression screening (PHQ-9) into standard heart failure clinic visits, ensuring appropriate anticoagulation for AF to prevent embolic stroke, and prescribing supervised exercise rehabilitation as a dual cardiac-neurological preventive intervention represent actionable steps for cardiologists to address the heart-brain axis in daily IC management. The high prevalence of cognitive impairment (50-75%) and depression (20-35%) in heart failure patients underscores why these conditions should be systematically assessed and treated as part of comprehensive IC care rather than incidentally discovered during crises. The bidirectional heart-brain interaction in heart failure extends to the autonomic nervous system, where chronic sympathetic overdrive in heart failure produces not only arrhythmias and LV remodeling but also direct neural damage to hippocampal neurons through excessive norepinephrine exposure and oxidative stress — making neurohormonal blockade with beta-blockers and RAAS inhibitors simultaneously cardioprotective and potentially neuroprotective, addressing both sides of the heart-brain axis with standard GDMT. Romanian cardiologists managing heart failure patients in heart failure clinics and during hospitalizations should incorporate brief cognitive screening and depression assessment into standard evaluation, recognizing that identifying and managing these comorbidities improves treatment adherence, quality of life, and potentially long-term survival in this complex patient population. Heart failure and the heart-brain axis (QJM 2023, PMID 37481714) provides cardiologists and neurologists with a comprehensive evidence-based review of the complex bidirectional interactions between cardiac dysfunction and neurological/psychiatric comorbidities, emphasizing that optimal heart failure management requires attention to the full brain-heart continuum — from preventing embolic stroke through anticoagulation to screening for depression and cognitive decline, and prescribing cardiac rehabilitation that simultaneously improves cardiac function and cerebral health. The high prevalence of undiagnosed cognitive impairment (50-75% of HF patients) and depression (20-35%) in heart failure, both associated with significantly worse outcomes, makes routine assessment of these conditions an essential quality indicator for heart failure programs — analogous to LDL measurement for ASCVD or HbA1c monitoring for diabetes management, but currently far less systematically implemented in standard heart failure clinic protocols. Future directions in heart-brain axis research include clinical trials of neurological interventions (cognitive rehabilitation, depression treatment) specifically powered to detect effects on heart failure outcomes, neuroimaging studies correlating cerebral perfusion with cardiac output to characterize the dose-response relationship between cardiac dysfunction and brain injury, and biomarker studies identifying which heart failure patients are at highest risk for cognitive decline to guide intensive neurological monitoring and preventive strategies.

Integrarea screeningului cognitiv și al depresiei în vizitele standard, anticoagularea pentru FA și prescrierea cardiorecuperării.

Heart failure and the heart-brain axis https://pubmed.ncbi.nlm.nih.gov/37481714/